Backgrounds
Methods
Patients and follow-up
NLR measurement
AUC | 95% CI | Cutoff | Youden index | Sensitivity | Specificity | P-value | ||
---|---|---|---|---|---|---|---|---|
Lower | Upper | |||||||
NLR | 0.829 | 0.735 | 0.924 | 3.3 | 0.652 | 77% | 91% | 0.000 |
Immunohistochemistry
AUC | 95% CI | Cutoff | Youden index | Sensitivity | Specificity | P-value | ||
---|---|---|---|---|---|---|---|---|
Lower | Upper | |||||||
CD34 | 0.931 | 0.876 | 0.986 | 26 | 0.757 | 82% | 93% | 0.000 |
Statistical analysis
Results
Clinicopathological charateristics of the patients
Association between NLR and CD34 respectively with clinicopathological characteristics of the patients
Patients and tumor characteristics | n(%) | NLR | χ2 | P-value | |
---|---|---|---|---|---|
≤3.3 | >3.3 | ||||
PSA level (ng/ml) | |||||
< 10 | 19 (25.3) | 12 (63.2) | 7 (36.8) | 8.248 | 0.016 |
10 ~ 20 | 29 (38.7) | 14 (48.3) | 15 (51.7) | ||
> 20 | 27 (36.0) | 6 (22.2) | 21 (77.8) | ||
Gleason score | |||||
≤ 6 | 14 (18.7) | 10 (71.4) | 4 (28.6) | 6.797 | 0.033 |
7 | 28 (37.3) | 12 (42.9) | 16 (57.1) | ||
8 ~ 10 | 33 (44.0) | 10 (30.3) | 23 (69.7) | ||
T stage | |||||
T1–2 | 33 (44.0) | 21 (63.6) | 12 (36.4) | 10.593 | 0.001 |
T3–4 | 42 (56.0) | 11 (26.2) | 31 (73.8) | ||
Lymph node metastasis | |||||
N0 | 46 (61.3) | 27 (58.7) | 19 (41.3) | 12.495 | 0.000 |
N1 | 29 (38.7) | 5 (17.2) | 24 (82.8) | ||
Distant metastasis | |||||
M0 | 43 (57.3) | 25 (58.1) | 18 (41.9) | 9.863 | 0.002 |
M1 | 32 (42.7) | 7 (21.9) | 25 (78.1) | ||
TNM stage | |||||
Stage II | 26 (34.7) | 17 (65.4) | 9 (34.6) | 8.396 | 0.004 |
Stage III ~ IV | 49 (65.3) | 15 (30.6) | 34 (69.4) |
Patients and tumor characteristics | n(%) | CD34 | χ2 | P-value | |
---|---|---|---|---|---|
≤26 | >26 | ||||
PSA level (ng/ml) | |||||
< 10 | 19 (25.3) | 14 (73.7) | 5 (26.3) | 7.465 | 0.024 |
10 ~ 20 | 29 (38.7) | 13 (44.8) | 16 (55.2) | ||
> 20 | 27 (36.0) | 9 (33.3) | 18 (66.7) | ||
Gleason score | |||||
≤ 6 | 14 (18.7) | 11 (78.6) | 3 (21.4) | 9.731 | 0.008 |
7 | 28 (37.3) | 15 (53.6) | 13 (46.4) | ||
8 ~ 10 | 33 (44.0) | 10 (48.0) | 23 (69.7) | ||
T stage | |||||
T1–2 | 33 (44.0) | 24 (72.7) | 9 (27.3) | 14.436 | 0.000 |
T3–4 | 42 (56.0) | 12 (28.6) | 30 (71.4) | ||
Lymph node metastasis | |||||
N0 | 46 (61.3) | 27 (58.7) | 19 (41.3) | 5.452 | 0.020 |
N1 | 29 (38.7) | 9 (31.0) | 20 (69.0) | ||
Distant metastasis | |||||
M0 | 43 (57.3) | 28 (65.1) | 15 (34.9) | 11.829 | 0.001 |
M1 | 32 (42.7) | 8 (25) | 24 (75.0) | ||
TNM stage | |||||
Stage II | 26 (34.7) | 18 (69.2) | 8 (30.8) | 7.187 | 0.007 |
Stage III ~ IV | 49 (65.3) | 18 (36.7) | 31 (63.3) |
Without disease progression | Disease progression | t | P-value | |
---|---|---|---|---|
NLR | 2.37 ± 1.58 | 5.56 ± 2.19 | 3.865 | 0.011 |
CD34 | 21.48 ± 11.55 | 37.26 ± 10.71 | 4.392 | 0.000 |
Correlation between NLR/CD34 and clinicopathological characteristics of prostate cancer patients
Patients and tumor characteristics | NLR/CD34 | Standard Deviation | P-value | |||
---|---|---|---|---|---|---|
NLRLow/CD34Low | NLRLow/CD34High | NLRHigh/CD34Low | NLRHigh/CD34High | |||
PSA level (ng/ml) | ||||||
< 10 | 8 (42.1) | 1 (5.3) | 5 (26.3) | 5 (26.3) | 0.169 | 0.011 |
10 ~ 20 | 10 (34.5) | 6 (20.7) | 4 (13.8) | 9 (31.0) | 0.142 | |
> 20 | 3 (11.1) | 4 (14.8) | 6 (22.2) | 14 (51.9) | 0.050 | |
Gleason score | ||||||
≤ 6 | 6 (42.9) | 3 (21.4) | 3 (21.4) | 2 (14.3) | 0.227 | 0.005 |
7 | 11 (39.3) | 2 (7.1) | 8 (28.6) | 7 (25.0) | 0.161 | |
8 ~ 10 | 4 (12.1) | 6 (18.2) | 4 (12.1) | 19 (57.6) | 0.059 | |
T stage | ||||||
T1–2 | 15 (45.5) | 4 (12.1) | 7 (21.2) | 7 (21.2) | 0.196 | 0.018 |
T3–4 | 6 (14.3) | 7 (16.7) | 8 (19.0) | 21 (50.0) | 0.084 | |
Lymph node metastasis | ||||||
N0 | 18 (39.1) | 8 (17.4) | 11 (23.9) | 9 (19.6) | 0.201 | 0.011 |
N1 | 3 (10.3) | 3 (10.3) | 4 (13.8) | 19 (65.6) | 0.173 | |
Distant metastasis | ||||||
M0 | 16 (37.2) | 9 (20.9) | 7 (16.3) | 11 (25.6) | 0.282 | 0.029 |
M1 | 5 (15.6) | 2 (6.3) | 8 (25.0) | 17 (53.1) | 0.186 | |
TNM stage | ||||||
Stage II | 19 (73.1) | 2 (7.7) | 2 (7.7) | 3 (11.5) | 0.195 | 0.000 |
Stage III ~ IV | 2 (4.1) | 9 (18.4) | 13 (26.5) | 25 (51.0) | 0.067 |